Autonomix Medical Secures U.S. Patent for Overactive Bladder Platform — Autonomix Medical, Inc.

Event summary

Autonomix Medical received U.S. Patent No. 12,611,134 for its overactive bladder (OAB) diagnosis and treatment platform on July 15, 2026.
The patent covers a catheter-based system designed for minimally invasive access through the urethra to sense and treat OAB directly at the bladder wall.
Autonomix's intellectual property portfolio now includes 112 issued or pending patent applications worldwide.
The company's technology platform is scalable, with potential applications across multiple organ systems.

The big picture

Autonomix Medical's new patent expands its neural sensing technology into the urology market, addressing a significant unmet need. The company's strategy of developing organ-specific applications from a single, scalable core technology positions it to compete in diverse clinical indications. With a comprehensive intellectual property portfolio extending into the late 2030s, Autonomix is well-positioned to capitalize on the growing demand for precision nerve-targeted treatments.

What we're watching

Market Expansion: How Autonomix will leverage this patent to penetrate the large urology market affecting approximately 37 million Americans.
Technology Scalability: Whether Autonomix can successfully develop organ-specific applications from its single, scalable core technology.
Regulatory Approval: The pace at which Autonomix can secure regulatory approvals for its implantable bladder device and other future applications.